Julius Knowles

Insider Reports History

Entity
Individual
Location
C/O Keros Therapeutics, Inc., 99 Hayden Avenue, Suite 120, Building E, Lexington, MA
Signature
/s/ Keith Regnante, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Julius Knowles:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Keros Therapeutics, Inc. Director Stock Option (right to buy) 10K May 30, 2024 Direct

Insider Reports Filed by Julius Knowles

Symbol Company Period Transactions Value $ Form Type Date Filed Role
KROS Keros Therapeutics, Inc. May 30, 2024 1 $0 4 Jun 3, 2024 Director
KROS Keros Therapeutics, Inc. Jun 6, 2023 1 $0 4 Jun 8, 2023 Director
KROS Keros Therapeutics, Inc. Jun 1, 2022 1 $0 4 Jun 3, 2022 Director
KROS Keros Therapeutics, Inc. Jan 3, 2022 24 -$2.76M 4 Jan 5, 2022 Director
KROS Keros Therapeutics, Inc. Dec 1, 2021 16 -$2.58M 4 Dec 3, 2021 Director
KROS Keros Therapeutics, Inc. Nov 1, 2021 12 -$2.01M 4 Nov 3, 2021 Director
KROS Keros Therapeutics, Inc. Oct 19, 2021 8 -$328K 4 Oct 21, 2021 Director
KROS Keros Therapeutics, Inc. Oct 14, 2021 12 -$1.02M 4 Oct 18, 2021 Director
KROS Keros Therapeutics, Inc. Oct 1, 2021 6 -$509K 4 Oct 5, 2021 Director
KROS Keros Therapeutics, Inc. Sep 27, 2021 6 -$3.92M 4 Sep 29, 2021 Director
KROS Keros Therapeutics, Inc. Jul 1, 2021 10 -$1.97M 4 Jul 6, 2021 Director
KROS Keros Therapeutics, Inc. Jun 4, 2021 16 -$953K 4 Jun 8, 2021 Director
KROS Keros Therapeutics, Inc. Jun 1, 2021 20 -$1.4M 4 Jun 3, 2021 Director
KROS Keros Therapeutics, Inc. Jun 1, 2021 1 $0 4 Jun 3, 2021 Director
KROS Keros Therapeutics, Inc. Apr 13, 2020 1 $25K 4 Jan 20, 2023 Director